



Lypro Biosciences Announces Issuance of US Patent for NanoDisk Drug Delivery Platform

November 2, 2010

San Francisco, CA – Lypro Biosciences, Inc. (Lypro Bio), announced that the United States Patent and Trademark Office has issued US Patent 7,824,709 covering composition of matter, process, and methods of use for its novel drug delivery nanotechnology, NanoDisk. NanoDisk are elegant, ternary complexes comprised of a scaffold which binds and stabilizes a lipid bilayer into which therapeutic compounds are incorporated. NanoDisk increases the solubility and bioavailability of the therapeutic compound yielding a more potent and efficacious therapy. Furthermore NanoDisk technology facilitates targeting of drugs to specific cell receptors. This proprietary technology can be brought to bear in a number of disease areas including infectious disease, oncology, and enzyme replacement. Lypro Bio has exclusive rights to the patent technology.

The patent prosecution was led by Gladys Monroy of Morrison Foerster. Similar claims have already issued in India and Australia.

“The U.S. patent broadly covers the NanoDisk drug delivery technology, allowing any number of therapeutic compounds to be incorporated. We are confident that the patent will provide our products with long-term market exclusivity,” said Michelle S. Call, President and CEO of Lypro Biosciences.

About Lypro Biosciences

Lypro Biosciences, Inc. is preclinical stage therapeutic company, located in the San Francisco Bay Area and financed by angel investors including Life Science Angels. Lypro Bio’s proprietary nanotechnology drug delivery platform, NanoDisk, has applications across numerous disease indications. Its product pipeline includes therapies for infectious diseases such as aspergillosis and leishmaniasis, as well as for cancers such as mantle cell lymphoma.

Contacts:

Michelle S. Call
President and CEO
Lypro Biosciences, Inc.
info@lyprobio.com
www.lyprobio.com
